<DOC>
	<DOC>NCT00522951</DOC>
	<brief_summary>This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.</brief_summary>
	<brief_title>SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Japanese patients at least 20 years of age Patients with diagnosed primary cancer Patients with metastatic lesions by CT/MRI Patients who have contraindication to the MRI examinations Patients who have severe renal disorder Patients in extremely serious general condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>MRI</keyword>
	<keyword>Brain Metastasis</keyword>
	<keyword>Gadolinium</keyword>
	<keyword>Imaging</keyword>
	<keyword>Diagnostic Agent</keyword>
</DOC>